Cystic fibrosis (CF), also known as mucoviscidosis, is a lethal common autosomal-recessive disorder. The disease is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), an anion channel that helps maintain fluid and electrolyte-homeostasis in multiple organs, including the lungs and pancreas. The treatment options include: airway-clearance techniques and medications to clear mucus from the lungs; proactive treatment of infections; pancreatic enzyme replacement therapy (PERT); optimal nutrition; and an active lifestyle. Ivacaftor (Kalydeco) was the first drug approved by the US Food and Drug Administration (FDA) in 2012, however it remains very expensive. Other medications used to treat patients with cystic fibrosis may include the following: multivitamins (including fat-soluble vitamins), nebulized, inhaled, oral, or intravenous antibiotics, bronchodilators, anti-inflammatory agents, agents to treat associated conditions or complications (insulin, bisphosphonates), and agents devised to potentially reverse the abnormalities in chloride transport (ivacaftor (Kalydeco), lumacaftor/ivacaftor). A number of promising CF products with different modes of action are in the developmental pipeline. The candidate drugs that remain on the current development pipeline include Ataluren (Translarna), CFTR gene therapy, Lynovex, Alpha‑1 antitrypsin, Sildenafil (Revatio), Levofloxacin (Aeroquin), Arikace (inhaled amikacin), AeroVanc (inhaled vancomycin), Liprotamase, OligoG, etc.
The global cystic fibrosis drugs market segmentation is based on drug class – anti-infectives, CF transmembrane conductance regulator (CFTR) modulators, mucolytics, and pancreatic enzyme replacement therapy (PERT).
The global cystic fibrosis drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global cystic fibrosis drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global cystic fibrosis drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global cystic fibrosis drugs market and profiled in this report include AbbVie, AlgiPharma, Aptalis Pharma, Cystic Fibrosis Foundation (CFF), Eli Lilly, Genentech (Roche), Grifols, Insmed, KaloBios Pharmaceuticals, N30 Pharmaceuticals, NovaBiotics, Novartis, Pharmaxis, PTC Therapeutics, Savara Pharmaceuticals, UK Cystic Fibrosis Gene Therapy Consortium (CFGTC), and Vertex Pharmaceuticals.